These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38711321)

  • 1. Factors Affecting the Discrepancy Between Coagulation Times on Extracorporeal Circulation Using Unfractionated Heparin in Children and Young Adults.
    Haga T; Misaki Y; Sakaguchi T; Akamine Y
    Clin Appl Thromb Hemost; 2024; 30():10760296241252838. PubMed ID: 38711321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance between ROTEM® clotting time and conventional tests during unfractionated heparin-based anticoagulation in intensive care patients on extracorporeal membrane oxygenation.
    Prakash S; Wiersema UF; Bihari S; Roxby D
    Anaesth Intensive Care; 2016 Jan; 44(1):85-92. PubMed ID: 26673593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact and Statistical Analysis of a Multifaceted Anticoagulation Strategy in Children Supported on ECMO: Performance and Pitfalls.
    Kessel AD; Kline M; Zinger M; McLaughlin D; Silver P; Sweberg TM
    J Intensive Care Med; 2017 Jan; 32(1):59-67. PubMed ID: 26319579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated Clotting Time (ACT) for Monitoring of Low-Dose Heparin: Performance Characteristics in Healthy Adults and Critically Ill Patients.
    Wehner JE; Boehne M; David S; Brand K; Tiede A; Bikker R
    Clin Appl Thromb Hemost; 2020; 26():1076029620975494. PubMed ID: 33350327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols.
    Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C
    Blood; 2015 Oct; 126(18):2091-7. PubMed ID: 26239090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
    Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
    Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
    Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
    Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-response study in animals to evaluate the anticoagulant effect of the stage 2 unfractionated heparin USP monograph change.
    Honchel R; Carraway J; Gopee N; Callicott R; Chen J; Patton R; Xu Q; Zalkkar J; Laniyonu A; Krefting I; Cato M; Robie-Suh K; Rieves R
    Regul Toxicol Pharmacol; 2011 Aug; 60(3):318-22. PubMed ID: 21549797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation Complications.
    McMichael ABV; Hornik CP; Hupp SR; Gordon SE; Ozment CP
    ASAIO J; 2020 Mar; 66(3):307-313. PubMed ID: 30883406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy.
    Liu Y; Yuan Z; Han X; Song K; Xing J
    Hamostaseologie; 2023 Jun; 43(3):171-178. PubMed ID: 35882351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients.
    Fitousis K; Klasek R; Mason PE; Masud F
    Perfusion; 2017 Apr; 32(3):238-244. PubMed ID: 27837164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heparin resistance and antithrombin deficiency].
    Maurin N
    Med Klin (Munich); 2009 Jun; 104(6):441-9. PubMed ID: 19533051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model.
    Berk ZBK; Shah A; Sun W; Griffith BP; Wu ZJ
    Artif Organs; 2022 Mar; 46(3):501-505. PubMed ID: 34698388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Influence of Haemostatic System Maturation on the Dose-Response Relationship of Unfractionated Heparin.
    Derbalah A; Duffull S; Moynihan K; Al-Sallami H
    Clin Pharmacokinet; 2021 Apr; 60(4):491-499. PubMed ID: 33128209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.